- Posts by Rachael GreyAssociate
Health care entities and other employers rely on attorney Rachael Grey for advice and counsel on employment law matters such as disability accommodations, discrimination and harassment, leaves of absence, wage and hour ...
Clinical laboratories still face uncertainty and the difficult decision of whether to start the work needed to comply with the with Phase 1 expectations under FDA’s Laboratory Developed Tests Final Rule (the “LDT Final Rule”), which remain set to go into effect on May 6, 2025. To be sure, the shift in priorities of the new administration has kept the health care industry on its toes for the last few weeks, especially as the leadership and messaging of the Department of Health and Human Services (“HHS”) has started to come into sharper focus. The theme of ‘deregulation’, particularly when it comes to the activities of the Food and Drug Administration (“FDA”), has sparked interest and discussion among stakeholders in the life sciences industry – including clinical laboratories that are weighing how to approach the upcoming May 6 deadline for compliance.
We discussed the details of the LDT Final Rule in a previous Insight, explaining that as of the May 6, 2025 Phase 1 deadline FDA will expect all laboratories that manufacture LDTs to comply with medical device reporting (“MDR”) requirements, correction and removal reporting requirements, and quality system (“QS”) requirements regarding complaint files.
Blog Editors
Recent Updates
- Video: Federal Court Strikes Down FDA Rule on LDTs – Thought Leaders in Health Law
- Medicare Drug Price Negotiation Program: The Inflation Reduction Act “Pill Penalty” and Other IRA Reforms on the Horizon for 2026
- Similar Language But a Different Outcome: Medicare DSH Payments after Advocate Christ Medical Center v. Kennedy
- Attorney General Issues Guidance to U.S. Department of Justice Regarding Transgender Healthcare for Children
- As State Legislatures Debate Strengthening the Corporate Practice of Medicine Limitations, a Drug Manufacturer’s Lawsuits Shine a Light on the Relationship Between Telehealth Companies and Affiliated Medical Groups